Tom 16, Nr 1 (2022)
Inne materiały uzgodnione z Redakcją
Opublikowany online: 2022-03-03
Wyświetlenia strony 1928
Wyświetlenia/pobrania artykułu 17
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Profilaktyka zakrzepowo-zatorowa u pacjentów z migotaniem przedsionków – w pytaniach i odpowiedziach

Michał Bączek12, Beata Wożakowska-Kapłon12, Agnieszka Ciba-Stemplewska3
Forum Medycyny Rodzinnej 2022;16(1):11-17.

Streszczenie

brak

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4(1): e001486.
  2. Pisters R, Nieuwlaat R, Lane DA, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263–272.
  3. Lip GY, Giugliano R. Can we predict stroke in atrial fibrillation? Clin Cardiol. 2012; 35: 21–27.
  4. Sticherling C, Marin F, Birnie D, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015; 17(8): 1197–1214.
  5. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016; 37(20): 1591–1602.
  6. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5): 1093–1100.
  7. Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2009; 361(12): 1139–1151.
  8. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
  9. Granger C, Alexander J, McMurray J, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011; 365(11): 981–992.
  10. Giugliano RP, Ruff CT, Braunwald E. ENGAGE AF TIMI Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
  11. Gorczyca I, Jelonek O, Uziębło-Życzkowska B, et al. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. J Clin Med. 2020; 9(11).
  12. Siontis KC, Zhang X, Schaubel DE, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018; 138(15): 1519–1529.
  13. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857–867.
  14. Steffel J, Collins R, Antz M, et al. External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10): 1612–1676.
  15. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021; 26(9): 4701.